AxoGen ( (AXGN) ) has released its Q1 earnings. Here is a breakdown of the information AxoGen presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Axogen, Inc. is a leading company specializing in the development and commercialization of surgical solutions for peripheral nerve injuries, offering innovative products aimed at restoring nerve function and improving patients’ quality of life. In its latest earnings report for the first quarter of 2025, Axogen reported a significant revenue increase of 17.4% compared to the same period last year, reaching $48.6 million, although its gross margin decreased to 71.9% from 78.8%. The company also reduced its net loss to $3.8 million, a notable improvement from the $6.6 million loss in the first quarter of 2024, and achieved an adjusted EBITDA of $2.9 million, up from $1.0 million. Key highlights include broad-based revenue growth across all product lines and significant regulatory progress with the FDA for its Avance Nerve Graft. Looking ahead, Axogen maintains its full-year revenue growth guidance of 15% to 17% and expects to be net cash flow positive, reflecting confidence in its strategic priorities and market development objectives.